Ashburner, Jeffrey M.
Atlas, Steven J.
Khurshid, Shaan
Weng, Lu-Chen
Hulme, Olivia L.
Chang, Yuchiao
Singer, Daniel E.
Ellinor, Patrick T.
Lubitz, Steven A.
Article History
Received: 13 February 2018
Revised: 20 June 2018
Accepted: 18 July 2018
First Online: 3 August 2018
Compliance with Ethical Standards
:
: Dr. Ashburner presented this study as a finalist during the Samuel A. Levine Young Clinical Investigator Award Competition at the American Heart Association Scientific Sessions on November 11, 2017.
: Dr. Lubitz is supported by NIH grants K23HL114724 and a Doris Duke Charitable Foundation Clinical Scientist Development Award 2014105. Dr. Hulme and Lubitz were supported by Grant 2016077 from the Doris Duke Charitable Foundation. Dr. Ashburner has received grant funding from Boehringer Ingelheim and Bristol-Myers Squibb. Dr. Ellinor is the principal investigator on a grant from Bayer to the Broad Institute related to mechanism and therapeutics of atrial fibrillation. Dr. Lubitz receives sponsored research support from Bayer HealthCare, Biotronik, Bristol-Myers Squibb, and Boehringer Ingelheim and has consulted for St. Jude Medical and Quest Diagnostics. Dr. Singer serves as a consultant or on the advisory board for Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Johnson and Johnson, Medtronic, and Pfizer; he has funding from research grants from Boehringer Ingelheim, Bristol-Myers Squibb, and Medtronic related to preventing stroke in atrial fibrillation. Dr. Atlas has received grant funding from Boehringer Ingelheim and Bristol-Myers Squibb.